Observational (registry)
Combination ProductObservational (Patient Registry)
NCT Number: NCT05188612
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Interested in participating?
Request Info18 year and older
All sexes
Observational
University of Bologna, Bologna, Italy
To address existing gaps in knowledge on CVD among European countries at different income levels, a collaboration of outcomes-oriented researchers from the University of Bologna partnered with Central and East European (CEE) countries researchers to conduct the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) investigating underlying threats in patients' CVD health status (NCT01218776).
In response to the COVID-19 crisis, ISACS-TC has promoted a new registry of the existing and further centers of the same geographic areas to support clinical research to prevent, and treat the COVID-19 illness. These efforts are made possible by the generous contributions of clinical research volunteers in some of the countries participating to the prior acute coronary syndrome network.
Scientific and clinical evidence is evolving on the effects of COVID-19, which can affect multiple organ systems. As, so the COVID-19 pandemic underscores the urgent need for coordination, collaboration, and information-sharing among researchers worldwide. Researchers of many disciplines have, therefore, joined the ISACS-TC investigators to build a multi-disciplinary registry investigating the impact of COVID-19.
Projects should be mainly focused on topics related to:
One trained physician will critically review the patients' reported symptoms and will assess SARS-CoV-2 IgG at each visit. In addition, wherever needed, the investigators will investigate the daily living status of survivors of COVID-19 using telephone interview questionnaires including Activity Daily Living (ADL), Self-rating Depression Scale (SDS), and New York Heart Association (NYHA) functional class.
National Investigators:
Bosnia and Herzegovina: Local PI: Mirza Dilic (Clinical Center University of Sarajevo)
Croatia: Local PI: Davor Miličić (University Hospital Center Zagreb)
Other Investigators:
Italy: Local PI: Stefano Nava (University of Bologna)
Other Investigators:
Macedonia: Local PI: Sasko Kedev and Marija Vavlukis (University "Ss. Cyril and Methodius")
Other Investigators:
Serbia: Local PI: Marija Zdravkovic (Hospital Medical Center Bezanijska kosa, Belgrade), Zorana Vasiljevic (University of Belgrade)
Other Investigators:
Spain: Local PI: Teresa Padro (IR-Hospital de la Santa Creu i Sant Pau, UAB, Barcelona)
Other Investigators:
United Kingdom: Local PI: Charalambos Antoniades (Oxford University)
Other Investigators:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational (Patient Registry)
Time frame: 30-day
Occurrence of all cause death
Time frame: 6 month
Occurrence of all cause death
Time frame: 12-month
Occurrence of all cause death
Time frame: 30 day, 6 -12 months
Occurrence of heart failure or worsening of preexisting heart failure (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of kidney disease or worsening of preexisting kidney failure (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of respiratory insufficiency or worsening of preexisting respiratory insufficiency (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of pneumonia (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of sepsis (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of SIRS (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of thrombosis and thromboembolism (According to the attending physician)
Time frame: 30 day, 6 -12 months
Occurrence of clinically relevant bleeding (According to the attending physician)
Time frame: 30 day, 6 -12 months
(According to the attending physician)
Time frame: 30 day, 6 -12 months
(According to the attending physician)
Contact information is provided by the study sponsor or research team.
Olivia Manfrini, MD
CONTACT
Raffaele Bugiardini, MD
CONTACT
University of Bologna
Other
International Survey of Acute Coronavirus Syndromes (ISACS)-COVID-19
Acronym: ISACS-COVID-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05787327
COVID-19, Coronaviridae Infections
Hong Kong
View Trial DetailsNCT07536308
COVID-19, Coronaviridae Infections
Decatur, Georgia, United States
View Trial DetailsNCT01306084
Adenoviridae Infections, Anogenital Herpes
Bethesda, Maryland, United States
View Trial DetailsNCT04330599
COVID-19, Coronaviridae Infections
London, County (optional), United Kingdom
View Trial Details